KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We here expand the phenotypic spectrum associated with genetic variants in ATP13A2 that previously comprised Kufor-Rakeb syndrome, spastic paraplegia 78, and neuronal ceroid lipofuscinosis type 12 (CLN12), to also include juvenile-onset ALS, as supported by both genetic and functional data.
|
30992063 |
2019 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We report two novel ATP13A2 pathogenic mutations, further expanding the phenotype of Kufor-Rakeb syndrome with the unusual features of ataxia and polyneuropathy.
|
31588715 |
2019 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ATP13A2 gene (PARK9, CLN12, OMIM 610513) were initially associated with a form of Parkinson's Disease (PD) known as Kufor Rakeb Syndrome (KRS).
|
31132336 |
2019 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
However, the mechanisms by which mutations in ATP13A2 cause KRS is not understood.
|
31393918 |
2019 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
BEFREE |
The P-type ATPase ATP13A2 protein was originally associated with a form of Parkinson's Disease (PD) known as Kufor Rakeb Syndrome (KRS).
|
29169913 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
BEFREE |
Loss of function mutations in the P<sub>5</sub>-ATPase ATP13A2 are associated with Kufor-Rakeb Syndrome and Neuronal Ceroid Lipofuscinosis.
|
28595912 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Loss of function mutations in the gene ATP13A2 are associated with Kufor-Rakeb Syndrome and Neuronal Ceroid Lipofuscinosis, the former designated as an inherited form of Parkinson's disease (PD).
|
29407413 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of ATP13A2, one of the four human P5B ATPases, leads to early-onset Parkinson's disease (Kufor-Rakeb Syndrome).
|
29547664 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Loss-of-function mutations in ATP13A2 are associated with three neurodegenerative diseases: a rare form of Parkinson's disease termed Kufor-Rakeb syndrome (KRS), a lysosomal storage disorder termed neuronal ceroid lipofuscinosis (NCL), and a form of hereditary spastic paraplegia (HSP).
|
29859891 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function mutations in ATP13A2 are associated with three neurodegenerative diseases: a rare form of Parkinson's disease termed Kufor-Rakeb syndrome (KRS), a lysosomal storage disorder termed neuronal ceroid lipofuscinosis (NCL), and a form of hereditary spastic paraplegia (HSP).
|
29859891 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Two affected siblings (born to non-consanguineous Jewish parents) presenting a similar KRS phenotype (onset age 27, 23), carried compound heterozygous pathogenic variants in ATP13A2: c.217_218insG and c.3057delC.
|
29966207 |
2018 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
UNIPROT |
Our biochemical and immunocytochemical experiments in COS-1 and HeLa cells and patient-derived fibroblasts demonstrated that the hereditary spastic paraplegia-associated mutations, similarly to the ones causing Kufor-Rakeb syndrome and neuronal ceroid lipofuscinosis, cause loss of ATP13A2 function due to transcript or protein instability and abnormal intracellular localization of the mutant proteins, ultimately impairing the lysosomal and mitochondrial function.
|
28137957 |
2017 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
BEFREE |
ATP13A2, which encodes a lysosomal P-type ATPase, has been identified as the causative gene for Kufor-Rakeb syndrome.
|
28894968 |
2017 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function mutations in ATP13A2 result in the Kufor-Rakeb Syndrome (KRS), a form of autosomal Parkinson's disease (PD).
|
28334751 |
2017 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Until now, fourteen mutations in ATP13A2 have been associated with KRS, while other mutations have been reported in association with neuronal ceroid lipofuscinosis (NCL) and early-onset PD.
|
26965689 |
2017 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Our biochemical and immunocytochemical experiments in COS-1 and HeLa cells and patient-derived fibroblasts demonstrated that the hereditary spastic paraplegia-associated mutations, similarly to the ones causing Kufor-Rakeb syndrome and neuronal ceroid lipofuscinosis, cause loss of ATP13A2 function due to transcript or protein instability and abnormal intracellular localization of the mutant proteins, ultimately impairing the lysosomal and mitochondrial function.
|
28137957 |
2017 |
KUFOR-RAKEB SYNDROME
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
Molecular diagnostic experience of whole-exome sequencing in adult patients.
|
26633545 |
2016 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
PHD2 inhibition was found to result in increased expression of ATP13A2, mutation of which is responsible for a rare juvenile form of PD known as Kufor-Rakeb syndrome.
|
26818499 |
2016 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and unanticipated rare disorders.
|
27165006 |
2016 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We recently showed that KRS/PARK9-linked mutations lead to several lysosomal alterations, including reduced proteolytic processing of cathepsin D in vitro.
|
27770614 |
2016 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Molecular diagnostic experience of whole-exome sequencing in adult patients.
|
26633545 |
2016 |
KUFOR-RAKEB SYNDROME
|
1.000 |
Biomarker
|
disease |
BEFREE |
ATP13A2 is a lysosomal P-type transport ATPase that has been implicated in Kufor-Rakeb syndrome and Parkinson's disease (PD), providing protection against α-synuclein, Mn(2+), and Zn(2+) toxicity in various model systems.
|
26134396 |
2015 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ATP13A2 (PARK9) gene cause early-onset, autosomal recessive Parkinson's disease (PD) and Kufor-Rakeb syndrome.
|
25461191 |
2015 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The importance of ATP13A2 (PARK9) in Parkinson's disease (PD) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome, an autosomal recessive, juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity, supranuclear gaze palsy, and dementia.
|
25900096 |
2015 |
KUFOR-RAKEB SYNDROME
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The present study also establishes that G2019S mutation leads to a reduction in lysosomal pH and increased expression of the lysosomal ATPase ATP13A2, a gene linked to a parkinsonian syndrome (Kufor-Rakeb syndrome), in brain samples from mouse and human LRRK2 G2019S carriers.
|
26251043 |
2015 |